University of Texas Texas AM Investment Management Co. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 339.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,662 shares of the medical research company's stock after buying an additional 1,284 shares during the quarter. University of Texas Texas AM Investment Management Co.'s holdings in Thermo Fisher Scientific were worth $865,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Barrett & Company Inc. purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $28,000. FPC Investment Advisory Inc. bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $28,000. Pillar Financial Advisors LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter worth about $29,000. Endeavor Private Wealth Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $30,000. Finally, Noble Wealth Management PBC purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth $35,000. Institutional investors own 89.23% of the company's stock.
Insiders Place Their Bets
In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares of the company's stock, valued at $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is owned by corporate insiders.
Thermo Fisher Scientific Price Performance
NYSE TMO traded down $0.79 during trading hours on Wednesday, reaching $402.76. The company's stock had a trading volume of 965,637 shares, compared to its average volume of 2,316,160. The firm has a market capitalization of $152.04 billion, a price-to-earnings ratio of 24.37, a P/E/G ratio of 2.99 and a beta of 0.82. The company's 50-day moving average is $437.74 and its two-hundred day moving average is $502.70. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 1-year low of $390.49 and a 1-year high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same quarter in the previous year, the company posted $5.11 EPS. The company's revenue was up .2% compared to the same quarter last year. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.
Wall Street Analyst Weigh In
Several brokerages have issued reports on TMO. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Wells Fargo & Company reduced their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Scotiabank decreased their price target on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research report on Friday, April 25th. Finally, Evercore ISI cut their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $607.43.
Check Out Our Latest Analysis on Thermo Fisher Scientific
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
See Also
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
